Differences in cardiac phenotype and natural history of laminopathies with and without neuromuscular onset by Ditaranto, R. et al.
RESEARCH Open Access
Differences in cardiac phenotype and
natural history of laminopathies with and
without neuromuscular onset
Raffaello Ditaranto1, Giuseppe Boriani2, Mauro Biffi1, Massimiliano Lorenzini1,3, Maddalena Graziosi1,
Matteo Ziacchi1, Ferdinando Pasquale1, Giovanni Vitale1, Alessandra Berardini1, Rita Rinaldi4, Giovanna Lattanzi5,
Luciano Potena1, Sofia Martin Suarez1, Maria Letizia Bacchi Reggiani1, Claudio Rapezzi1 and Elena Biagini1*
Abstract
Objective: To investigate differences in cardiac manifestations of patients affected by laminopathy, according to
the presence or absence of neuromuscular involvement at presentation.
Methods: We prospectively analyzed 40 consecutive patients with a diagnosis of laminopathy followed at a single
centre between 1998 and 2017. Additionally, reports of clinical evaluations and tests prior to referral at our centre
were retrospectively evaluated.
Results: Clinical onset was cardiac in 26 cases and neuromuscular in 14. Patients with neuromuscular presentation
experienced first symptoms earlier in life (11 vs 39 years; p < 0.0001) and developed atrial fibrillation/flutter (AF) and
required pacemaker implantation at a younger age (28 vs 41 years [p = 0.013] and 30 vs 44 years [p = 0.086] respectively),
despite a similar overall prevalence of AF (57% vs 65%; p= 0.735) and atrio-ventricular (A-V) block (50% vs 65%; p = 0.500).
Those with a neuromuscular presentation developed a cardiomyopathy less frequently (43% vs 73%; p = 0.089) and had a
lower rate of sustained ventricular tachyarrhythmias (7% vs 23%; p = 0.387). In patients with neuromuscular onset rhythm
disturbances occurred usually before evidence of cardiomyopathy. Despite these differences, the need for
heart transplantation and median age at intervention were similar in the two groups (29% vs 23% [p = 0.717]
and 43 vs 46 years [p = 0.593] respectively).
Conclusions: In patients with laminopathy, the type of disease onset was a marker for a different natural
history. Specifically, patients with neuromuscular presentation had an earlier cardiac involvement, characterized
by a linear and progressive evolution from rhythm disorders (AF and/or A-V block) to cardiomyopathy.
Keywords: Lamin, Emerin, Neuromuscular disorders, Atrial fibrillation, Bradyarrhythmias, Ventricular
tachycardias, Familial cardiomyopathies
Introduction
Laminopathies are a group of inherited conditions due to
mutations in the LMNA gene, that encodes the nuclear
envelope proteins lamin A and C, via alternate splicing [1].
Laminopathies are characterized by a high phenotypic
heterogeneity including heart disease, neuromuscular
disorders, premature aging and metabolic disorders [2–5].
LMNA associated cardiac and skeletal muscle disease -
often coexisting in the same patient - are the most frequent
clinical manifestations. The spectrum of cardiac involve-
ment ranges from supraventricular tachyarrhythmias and/
or conduction system disease to dilated cardiomyopathy
(DCM) and ventricular tachyarrhythmias [6–12]. Sudden
cardiac death may occur due to bradyarrhythmias or to
malignant ventricular arrhythmias [13], even in the pres-
ence of mild left ventricle systolic dysfunction. Similarly,
LMNA-related neuromuscular disorders are characterized
by a wide heterogeneity in clinical manifestations, Emery
Dreifuss muscular dystrophy (EDMD) being the most
common phenotype. EDMD is typically characterized by
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early onset joint contractures with slowly progressive
scapulo-humero-peroneal muscle weakness, and can be
caused by mutations in genes other than LMNA, mainly
EMD that encodes emerin.
Although clinical manifestation in patients with LMNA
mutations have been extensively described, the exact time
course of cardiological and neuromuscular disease and
their relation remain unclear. Specifically, it is not known
if a neuromuscular onset is associated with a different
cardiac phenotype or cardiac disease progression. The aim
of this study was therefore to investigate differences in
cardiac phenotype and natural history in relation to the
presence of neuromuscular involvement at presentation,
in patients with a diagnosis of laminopathy. Furthermore,
in order to test the hypothesis that neuromuscular presen-
tation (phenotype) per se might be associated with a spe-
cific cardiac natural history, irrespective of genetics, we
compared patients with neuromuscular presentation and
LMNA or EMD mutations.
Methods
In this observational study, we prospectively evaluated all
LMNA mutation carriers from a single Italian centre
(S.Orsola-Malpighi University Hospital, Bologna), between
December 1998 and November 2017. We also retrospect-
ively examined clinical, ECG and echocardiographic reports
available prior to evaluation at our centre. According to the
presence of signs and/or symptoms of skeletal myopathy at
clinical presentation (not necessarily in our centre), patients
were divided into two groups: “with neuromuscular onset”
and “without neuromuscular onset”. Data of 7 patients with
EMD-related disease were also recorded. All patients
underwent periodical clinical, electrocardiographic and
echocardiographic monitoring.
DCM was defined as the presence of left ventricular (LV)
dilation and systolic dysfunction in the absence of abnormal
loading conditions (hypertension or valve disease) or coron-
ary artery disease sufficient to cause global systolic impair-
ment [14]. “Hypokinetic non-dilated cardiomyopathy”
(HNDC) was defined as LV ejection fraction (EF) < 45% or
biventricular global systolic dysfunction in absence of dilata-
tion [15]. Restrictive cardiomyopathy was defined as a non-
dilated LV with normal wall thickness and EF, and severe
diastolic dysfunction with restrictive filling pattern, elevated
filling pressures and dilated atria [14]. Sustained ventricular
tachyarrhythmias (SVT) were defined as ventricular tachyar-
rhythmias with a rate ≥ 120/min, lasting > 30 s.
A neurological involvement was investigated on the
basis of personal history and/or symptoms including joint
contractures, muscle weakness or wasting, orthopaedic
surgery, and exercise tolerance. Electromyography (EMG),
muscle imaging or muscle biopsy were performed in se-
lected cases. Patients underwent periodical neurological
evaluation, even when no skeletal muscle involvement was
recorded at first evaluation. Elevation of serum creatine
kinase (CK) in isolation was not considered diagnostic of
neuromuscular involvement in absence of clinical, EMG,
imaging or histological evidence of skeletal myopathy.
A detailed family history was collected for each pro-
band in order to identify other potentially affected family
members. A genetic diagnosis was made by DNA se-
quencing from peripheral blood and mutations were
considered pathogenic if previously described in litera-
ture, in the presence of co-segregation or based on the
site and the type of mutation. After mutation identifica-
tion, cascade genetic screening was performed in family
members, following informed consent.
Continuous data distribution was assessed with the
Shapiro-Wilk test and expressed as median and interquar-
tile range (IQR). Data were compared by the Fisher’s exact
test for proportions, and Mann Whitney test for continu-
ous variables. Clinical events were reported as counts and
percentages (i.e. events/total number of patients × 100).
Data were collected following informed consent.
Results
Of the 41 LMNA mutation carriers, 40 were clinically af-
fected. Table 1 reports clinical, ECG and echocardio-
graphic characteristics at first evaluation at our centre.
Fourteen patients were assigned to the group “with
neuromuscular onset” and 26 to the group “without
neuromuscular onset”. A single LMNA mutation carrier,
who did not have any cardiac or neuromuscular pheno-
typic expression at baseline or during follow up, was ex-
cluded from the analysis.
Patients with neuromuscular onset
Among the 14 patients in this group males and females
were equally represented. LMNA mutations were: 12
missense, 1 splice site, and 1 deletion (Table 2). Median
age at first evaluation at our Centre was 31 years (IQR
20–44). The diagnosis of laminopathy occurred follow-
ing familial screening in 2 patients. At time of genetic
diagnosis, overt neuromuscular involvement was present
in all cases whereas none had cardiac involvement.
Eleven patients (79%) were diagnosed with EDMD in the
first or second decade of life and 3 (21%) were diagnosed
with a non-specific myopathy in the third decade; me-
dian age at diagnosis was 11 years (IQR 8–30).
Nine patients (64%) developed cardiac involvement prior
to referral to our centre (Fig. 1a summarizes the spectrum
of cardiac phenotypic expression). All had rhythm distur-
bances: 2 (14%) had atrial fibrillation (AF), 1 (7%) atrio-
ventricular (A-V) block, 1 (7%) sinus node dysfunction, and
5 (36%) had a combination of brady- and atrial tachyar-
rhythmias (Fig. 2). Cardiomyopathy was also present in 5
patients (36%): 2 DCM, 2 HNDC and 1 isolated right
ventricular cardiomyopathy mimicking arrhythmogenic
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right ventricular cardiomyopathy. Patients with LV cardio-
myopathy had a severe LV dysfunction (LVEF ≤35%) and 3
had biventricular involvement.
Two patients (14%) had previously undergone pace-
maker (PM) implantation for A-V block, while a single
patient had a primary prevention implantable cardiac
resynchronization therapy defibrillator (CRT-D). Serum
CK levels were raised in 65% of the patients, with a
mean abnormal value of 631 UI/L.
Patients without neuromuscular onset
Fifteen (58%) of the 26 patients were males, median age at
first evaluation at our centre was 43 years (IQR 36–49).
Diagnosis was made due to rhythm disturbances or heart
failure symptoms in most cases (n = 19, 73%). Seven pa-
tients (27%) were identified after family screening. LMNA
mutations were: 16 missense, 7 splice site, 2 deletion and
1 frameshift (Table 3).
At first clinical evaluation at our centre, 19 patients
(73%) had a cardiomyopathy, in isolation (n = 3, 11%) or
associated with arrhythmias (AF n = 5, 19%; A-V block
n = 6, 23%; both n = 5, 19%; Fig. 3). Seven patients (27%)
had arrhythmias in absence of cardiomyopathy: 1 (4%) AF,
5 (19%) A-V block and 1 (4%) a combination of sinus
node and A-V node dysfunction. Overall, AF was present
in 11 patients (42%). Figure 1b summarizes the spectrum
of cardiac phenotypic expression. Six patients (23%) had
previously undergone PM implantation for A-V block and
7 patients (27%) had received a primary prevention im-
plantable cardioverter defibrillator (ICD).
Cardiomyopathy phenotype included: 11 DCM, 6
HNDC and 2 restrictive cardiomyopathy. Among the
Table 1 Characteristics at first clinical evaluation at our centre of patients with LMNA mutations with and without neuromuscular
onset
Overall With neurological Onset Without neurological onset P value
Number of patients 40 14 (35) 26 (65)
Number of families 31 12 (39) 19 (61)
Males 22 (55) 7 (50) 15 (58) 0.744
Age at symptom onset, yrs 33 (21–42) 11 (8–30) 39 (32–46) < 0.0001
Age at first contact at our center, yrs 39 (29–74) 31 (20–44) 43 (36–49)
Follow-up duration, months 30 (6–70) 24 (12–101) 32 (8–63)
Diagnostic pathway
Signs or symptoms 12 (86) 19 (73) 0.452
Screening 2 (14) 7 (27)
Cardiomyopathy 24 (60) 5 (36) 19 (73) 0.040
Dilated CMP 13 (32) 2 (14) 11 (42) 0.089
Hypokinetic non dilated CMP 8 (20) 2 (14) 6 (23) 0.688
Restrictive CMP 2 (5) 0 2 (8) 0.533
Right ventricle CMP 1 (2) 1 (7) 0 0.350
History of atrial fibrillation 17 (42) 6 (43) 11 (42) 1.000
Sinus node dysfunction 4 (10) 3 (21) 1 (4) 0.114
Atrio-ventricular block 23 (57) 6 (43) 17 (65) 0.197
1st degree 8 (20) 2 (14) 6 (23)
2nd degree 7 (17) 2 (14) 5 (19)
3rd degree/high degree 8 (20) 2 (14) 6 (23)
Positive familial history for
Sudden death 7 (17) 3 (21) 4 (15) 0.678
PM implantation (high degree AVB) 11 (27) 3 (21) 8 (30) 0.715
CMP 16 (40) 5 (36) 11 (42) 0.746
NYHA class III- IV 7 (17) 4 (28) 3 (12) 0.214
PM recipients 8 (20) 2 (14) 6 (23) 0.688
ICD recipients 8 (20) 1 (7) 7 (27) 0.221
Values are expressed as N, N (%) or median (interquartile range)
LMNA, EMD gene codifying for lamin A/C and emerin, respectively, ICD implantable cardioverter defibrillator, PM pacemaker, AVB atrio-ventricular block, NYHA
New York Heart Association
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17 patients with LV systolic dysfunction, 7 (41%) had
a severe impairment (LVEF ≤35%), 6 (35%) had biventri-
cular involvement and 3 (17%) had increased LV trabecu-
lations. One 54-year old patient with a history of complete
A-V block and AF had a biventricular cardiomyopathy
with multiple aneurysms in the diaphragmatic and free
wall of the right ventricle. Coronary arteries were unob-
structed at angiography. Cardiac magnetic resonance
showed a severely dilated left ventricle (indexed end dia-
stolic volume: 146mL/m2) with systolic dysfunction (EF
40%) and mildly dilated right ventricle (indexed end dia-
stolic volume: 111ml/m2) with reduced EF (40%) and
confirmed the wall motion abnormalities (Fig. 4 a-b).
Tissue characterization (Fig. 4 c-d) revealed multiple
areas of fibro-fatty replacement. In this case, possible
phenocopies including desmosomal-related cardiomy-
opathy and sarcoidosis were excluded by genetic ana-
lysis, positron emission tomography, lung CT and,
endomyocardial biopsy.
No patient had evidence of neuromuscular involvement.
Serum CK levels were raised in 47% of the patients with a
mean abnormal value of 217 UI/L.
Follow-up of patients with neuromuscular onset
Median follow up was 24months (IQR 12–101). New onset
AF was recorded in 2 patients, therefore 57% experienced
atrial tachyarrhythmias by the end of the follow-up. In one
patient, the atrial conduction disease progressed to atrial
paralysis. Three patients underwent PM implantation for
A-V block (n = 1), sinus node disease (n = 1) or both (n =
1). A primary prevention CRT-D was implanted in a patient
with new onset HNDC due to positive family history for
sudden death, high inducibility of VT on electrophysio-
logical study and moderate LV dysfunction. The patient
affected by right ventricular cardiomyopathy received a
primary prevention ICD, due to severe right ventricular
dysfunction, non-sustained ventricular tachycardias and the
need of a pacing for sinus and A-V node dysfunction.
Table 2 Genetics of LMNA mutated patients with neurological onset (N = 14)
Gene Location Nucleotide Change Protein Change Predicted Effect
Family 1
F; 16 yo LMNA Exon 4 c.746G > A p.Arg249Gln Missense
Family 2
F; 50 yo LMNA Exon 9 c.1580G > C p.Arg.527.Pro Missense
Family 3
M; 38 yo LMNA Exon 11 c.1930C > T p.Arg644Cys Missense
M; 38 yo LMNA Exon 11 c.1930C > T p.Arg644Cys Missense
Family 4
F; 46 yo LMNA Exon 3
Exon 4
c.569G > A;






F; 34 yo LMNA Exon 1 c.203_208 (delAGGTGG) p.Glu68_Val69 del Deletion
Family 6
M; 52 yo LMNA Exon 4 c.746G > A p.Arg249Gln Missense
Family 7
M; 46 yo LMNA Exon 9 c.1567G > A p.Gly523Arg Missense
Family 8
M; 17 yo LMNA Exon 4 c.775 T > G p.Tyr259Asp Missense
Family 9
M; 19 yo LMNA Exon 4 c.746 G > A p.Arg249Gln Missense
Family 10
F; 29 yo LMNA Intron 9 c.1608 + 1G > T – Splice site
Family 11
F; 22 yo LMNA Exon 1 c.188 T > A p.Ile63Asn Missense
F; 19 yo LMNA Exon 1 c.188 T > A p.Ile63Asn Missense
Family 12
M; 27 yo LMNA Exon 4 c.746G > A p.Arg249Gln Missense
M male, F female, yo years old. The age reported refers to first contact at our centre
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Thereafter he experienced an appropriate ICD activation
and a progression towards severe biventricular involvement.
No sudden death occurred. Five patients with cardiomyop-
athy had hospital admissions due to heart failure during
follow-up and 4 of them subsequently underwent heart
transplantation (median age 43 [IQR 34–48]).
Follow-up of patients without neuromuscular onset
New onset AF was reported in 6 patients (23%) during a
median follow up of 32months (IQR 8–63); 65% of
patients had atrial tachyarrhythmias at the end of follow
up. With the exception of 2 patients with atrial flutter –
who were treated successfully with cavo-tricuspid isthmus
ablation – the attempts of rhythm control with electrical
or pharmacological cardioversion were ineffective. No pa-
tients underwent pulmonary vein isolation. Atrial paralysis
was documented in a single patient. One patient under-
went PM implantation due to A-V block. A primary pre-
vention ICD was implanted in 7 patients (4 new implants
and 3 device upgrades) and 1 ICD was implanted for
secondary prevention. Four of the ICD recipients (50%)
received a CRT-D device. During follow up 6 patients
(23%) experienced appropriate shocks and/or antitachycar-
dia pacing for ventricular arrhythmias, with an arrhythmic
storm in 3 cases. Six (23%) patients underwent cardiac
transplantation (median age 46 [IQR 34–53]) due to end
stage heart failure (5/6) or to recurrent ventricular arrhyth-
mias (1/6). One patient developed a mild neuromuscular
involvement, with muscle atrophy involving the shoulder
girdle. Table 4 compares clinical events reported during
follow-up in the two groups.
Differences in clinical manifestations between patients
with and without neuromuscular onset
Patients with neuromuscular onset had an earlier pres-
entation, during infancy or adolescence in most of the
cases (median age 11 years), mainly as EDMD, followed
by the first evidence of cardiac disease by a median age
of 13 years (IQR 10–15) (maximum timelag 38 years). In
patients without neuromuscular onset, first cardiac
symptoms occurred later in life, at a median age of 39
Fig. 1 a Cardiac phenotype spectrum at first clinical evaluation at
our centre of patients with LMNA mutations and neurological onset
(N = 14). SSS: sick sinus syndrome; AVB: atrio-ventricular block; CMP:
cardiomyopathy; AF atrial fibrillation/flutter. b Cardiac phenotype
spectrum at first clinical evaluation at our centre of patients with
LMNA mutations without neurological onset (N = 26). SSS: sick sinus
syndrome; AVB: atrio-ventricular block; CMP: cardiomyopathy; AF
atrial fibrillation/flutter
Fig. 2 Second degree sino-atrial block with 2:1 conduction ratio in a 22-year old female, with Emery Dreifuss muscular dystrophy due to
p.Ile63Asn missense LMNA mutation
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Table 3 Genetics and cardiac manifestations of LMNA mutated patients without neurological onset (N = 26)
Gene Location Nucleotide Change Protein Change Predicted Effect
Family 1
M; 53 yo LMNA Exon 6 c.1004G > A p.Arg335Gln Missense
M; 26 yo LMNA Exon 6 c.1004G > A p.Arg335Gln Missense
Family 2
F; 47 yo LMNA Exon 7 1370delA p.Lys457SerfsX2 Deletion
Family 3
M; 19 yo LMNA Exon 6 c.1003G > A p.Arg335Glu Missense
Family 4
F; 55 yo LMNA Exon 11 c.1912G > A p.Gly638Arg Missense
Family 5
M; 54 yo LMNA Exon 7 c.1202G > A p.Arg401His Missense
Family 6
M; 42 yo LMNA Exon 1 n/a p.Arg72Alafs*24 Frame shift
Family 7
F; 51 yo LMNA Exon 4 c.752A > C p.Gln251Pro Missense
Family 8
M; 46 yo LMNA Exon 9 c.1517 A > C p.His506Pro Missense
Family 9
F; 38 yo LMNA Intron 9 c1608 + 1G > T – Splice site
M; 35 yo LMNA Intron 9 c1608 + 1G > T – Splice site
Family 10
F; 29 yo LMNA Exon 3 c.548 T > C p.Leu183Pro Missense
Family 11
F; 41 yo LMNA Exon 6 c.1007G > A p.Arg336Gln Missense
Family 12
M; 60 yo LMNA Intron 1 c.357-1G > A
IVS1-1G > A
– Splice site
F; 46 yo LMNA Intron 1 c.357-1G > A
IVS1-1G > A
– Splice site
F; 49 yo LMNA Intron 1 c.357-1G > A
IVS1-1G > A
– Splice site
F; 49 yo LMNA Intron 1 c.357-1G > A
IVS1-1G > A
– Splice site




M; 38 yo LMNA Exon 6 c.1129C > T p.Arg377Cys Missense
Family 14
M; 50 yo LMNA Exon 2 c.481G > A p.Glu161Lys Missense
Family 15
M; 46 yo LMNA Exon 2 c.466C > A p.Arg156Ser Missense
M; 34 yo LMNA Exon 2 c.466C > A p.Arg156Ser Missense
Family 16
M; 44 yo LMNA Exon 4 c.671 C > T p.Thr224Ile Missense
Family 17
F; 39 yo LMNA Exon 2 c.481G > A p.Glu161Lys Missense
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years (p < 0.0001). Regarding arrhythmias, at the end of
the follow-up A-V block (of any degree) and AF had a
similar prevalence between the two groups (50% vs 65%,
p = 0.500 and 57% vs 65%; p = 0.735 respectively). Sinus
node dysfunction was more frequent in patients with skel-
etal myopathy (21% vs 4%; p = 0.114), whereas atrial par-
alysis was reported in one patient for each group. Patients
with neuromuscular presentation (Fig. 5) experienced
earlier AF (age 28 vs 41, p = 0.013) and PM implantation
(age 30 vs 44; p = 0.086). The percentage of patients
requiring permanent pacing (including PM recipients and
those who received an ICD due to a concomitant indica-
tion for prevention of ventricular arrhythmias) was equal
in the two groups (42% vs 42%; p = 1.000).
Patients without neuromuscular presentation had a
higher prevalence of cardiomyopathy (73% vs 43%, p =
0.089) and were older at diagnosis (age 42 vs 35, p = 0.259).
DCM was the dominant phenotype in this group (58% of
all cardiomyopathies), whereas DCM and HNDC where
equally represented in the other group. The higher preva-
lence of heart muscle involvement in patients without
neuromuscular onset was associated with a higher number
of implanted ICDs (58% vs 21%, p = 0.045) and a higher
burden of SVT (23% vs 7%, p = 0.387). Despite this, no sig-
nificant differences were reported in the prevalence of heart
transplantation (23% vs 29%; p = 0.717) or in the median
recipient age (43 vs 46; p = 0.593).
All patients with neuromuscular presentation who
received a diagnosis of cardiomyopathy had a previous
history of rhythm disturbance with the exception of 2
cases, where the diagnosis was concomitant. On the con-
trary, no pattern of progression from rhythm disturb-
ance to cardiomyopathy was present in those without a
neuromuscular presentations: AF and A-V block could
precede the diagnosis of cardiomyopathy, be diagnosed
at the same time or later. Figure 6 shows the different
Table 3 Genetics and cardiac manifestations of LMNA mutated patients without neurological onset (N = 26) (Continued)
Gene Location Nucleotide Change Protein Change Predicted Effect
Family 18
F; 37 yo LMNA Exon 2 c.513G > A pLys171Asn Missense
Family 19
F; 36 yo LMNA Exon 5 c.855delG p.Ala287LeufsX191 Deletion
M male, F female, yo years old. The age reported refers to first contact at our centre. n/a not available
Fig. 3 43-year old male with a LMNA frameshift mutation without neuromuscular presentation. a V1 lead ECG showing first degree atrio-
ventricular block, b-c cardiac magnetic resonance showing midwall late gadolinium enhancement in the basal interventricular septum.
Suggestive for myocardial fibrosis
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overall prevalence of clinical events between the two
populations.
Clinical characteristics and follow up of patients with
emerinopathy
Seven male patients (4 families) affected by X-linked
EDMD were referred to our Centre at a median age of
26 years (IQR 14–30) and followed for a median time of
108 months (IQR 72–172). All had neuromuscular
symptoms as first evaluation, with a median age of 6
years (IQR 5–8). At last follow up 6 patients (85%) had
cardiac involvement. All developed AF at a median age
of 27 [IQR 23–37]) and 5 required PM implantation at a
median age of 23 [IQR 22–24] due to A-V block (n = 1),
sinus node dysfunction (n = 1) or both (n = 3). A single
patient developed cardiomyopathy with mild systolic
dysfunction; none had ventricular arrhythmias. The time
interval from neurological to cardiac disease onset was
of 14,5 years (IQR 14–15). Compared to patients with
LMNA mutations and a neurological onset, patients with
emerinopathy presented a higher burden of AF (85% vs
57%; p = 0.337) that occurred an earlier age (27 vs 31
Fig. 4 CMR of a 54-year male, carrier of p.Arg401His missense LMNA mutation, affected by DCM. (a-b) Four chamber and RV long axis SSFP
images show biventricular dilation, bulging of the RV free wall (white arrow, panel a-b) and diaphragmatic wall (white arrow, panel b). (c) Two
chamber T1-weighted and (d) fat suppressed T1-weighted slices showing LV fatty replacement of mid lateral wall (white arrow). (e) IR LGE slice
showing fibrosis in the infero-lateral wall (with focal transmural pattern) and in the interventricular septum (image quality was due to respiratory
artifacts and to the presence of pacemaker [*]). CMR: cardiac magnetic resonance. DCM: dilated cardiomyopathy. SSFP: steady-state free
precession. LV-RV: left-right ventricle. IR LGE: inversion recovery late gadolinium enhancement
Table 4 Clinical events reported during follow-up in LMNA mutated patients
Patients with neurological onset (N = 14) Patients without neurological onset (N = 26) P value
New onset of atrial fibrillation (any form) 2 (14) 6 (23) 0.688
PM implantation 3 (21) 1 (4) 0.114
ICD implantation 2 (14) 8 (31) 0.445
SVT/arrhythmic storm 1 (7) 6 (23) 0.387
Admission for heart failure 5 (36) 11 (42) 0.746
Heart transplantation 4 (29) 6 (23) 0.717
Thromboembolic events 0 0
Values are expressed as N or N (%). SVT sustained ventricular tachyarrhythmia, PM pacemaker, ICD implantable cardioverter defibrillator
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p = 0.746), and a higher rate of PM implantation (71 vs
36%; p = 0.182) at an earlier age (23 vs 28; p = 0.461).
Differently, heart muscle involvement was rare (a single
case of cardiomyopathy) and no SVT was documented.
Discussion
The main findings of our study are: 1) neuromuscular on-
set is a marker for a specific natural history in laminopa-
thy patients. Specifically, these patients have a linear and
predictable progression over time, from muscular dys-
trophy to rhythm disturbances and finally cardiomyop-
athy. 2) With the exception of sinus node dysfunction,
that was more frequent in EDMD patients, the prevalence
of A-V block and AF was similar between the two groups,
but patients with a neuromuscular presentation had earl-
ier arrhythmias. 3) Prevalence of cardiomyopathy (particu-
larly DCM) and SVT was higher among patients without
neuromuscular onset, although the two groups had a simi-
lar rate and age of cardiac transplantation.
Most of the patients with neuromuscular presentation
(64%) developed cardiac involvement later in life: the delay
between neuromuscular and cardiac symptom onset was
variable and sometimes very long. These findings suggest
that serial reassessment of cardiac status in patients with a
diagnosis of EDMD is mandatory. On the other hand,
patients without neuromuscular onset did not develop an
overt skeletal myopathy (with a single exception). The pos-
sibility that these patients could develop neuromuscular
Fig. 5 Box and whiskers plot showing age distribution of different clinical events in LMNA patients with (white) and without (gray) neuromuscular
onset. Middle horizontal line inside box indicates median. Bottom and top of the box are 25th and 75th percentiles, the whiskers indicate the
lowest and highest value. PM: pacemaker. ICD: implantable cardioverter defibrillator
Fig. 6 Different overall prevalence at the end of follow-up of clinical events in LMNA patients with (white) and without (gray) neuromuscular
presentation. AF: atrial fibrillation; PM: pacemaker; CMP: cardiomyopathy; SVT: sustained ventricular tachycardias
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involvement in the future cannot however be entirely ruled
out due to the limited observation time. Our results are in
line with the phenotypic clustering reported by Benedetti
et al. [16] in a cohort of patients with LMNA mutations,
where those with childhood onset had an almost exclusively
skeletal muscle involvement (predominantly EDMD), while
patients with adult onset developed cardiac disorders or
muscle weakness with a limb-girdle distribution. With the
limitation of the small size of the screened families in our
study population and the limited numbers of relatives who
carried the mutation, all the affected relatives of probands
with neuromuscular presentation had a skeletal muscle
involvement as clinical onset. At the same time, all the af-
fected relatives of patients with an exclusive cardiac pheno-
type had an isolated cardiological involvement. Differently
from our findings, Bonne et al. and Brodsky et al. [17, 18]
have previously described the possibility of the coexistence
of both phenotypes as clinical onset within the same family.
Our data confirm the high frequency of AF in lamino-
pathies, as well as advanced A-V block, requiring PM
implantation at a young age. Although the prevalence of
high degree A-V block and AF was similar, irrespective
of clinical presentation, patients with neuromuscular on-
set experienced arrhythmia earlier in life (on average AF
and PM implantation occurred more than 10 years earl-
ier). On the other hand, sinus node dysfunction was
more frequent in patients with EDMD (21% vs 4%). Re-
garding heart muscle involvement, patients without
neuromuscular onset had a prevalence of cardiomyop-
athy that was almost twice that of the other group (42%
vs 73%; p = 0.089), mostly DCM. On the contrary DCM
and HNDC were equally distributed in patients with
neuromuscular presentation. A progression from HNDC
to DCM was not observed in this study, suggesting that
they could be the expression of two different pathophys-
iologic models; however, a limited follow-up duration
(median 41months) and heart failure therapy could have
masked this progression. We described two cases, 1 in
each group, with a cardiac phenotype that mimicked
arrhythmogenic cardiomyopathy. LMNA carriers have
been described with clinical, morphological and histo-
logical phenotypes overlapping with arrhythmogenic car-
diomyopathy [19], in the absence of desmosomal gene
mutations, with conduction disease being the sole ‘red
flag’ for the correct diagnosis. These findings may justify
the need to exclude LMNA mutations in patients with
suspected arrhythmogenic cardiomyopathy, particularly
when conduction disease is present.
This study confirms the malignant nature of laminopa-
thies in terms of ventricular arrhythmias and progression to
advanced heart failure. In our series sustained SVTs during
the follow-up were more frequent in patients without
neuromuscular involvement (23% vs 7%) with just 1 EDMD
patient experiencing SVT. The low incidence of events in
patients with skeletal myopathy differs from previous re-
ports. Van Rijsingen et al. [10] reported that in patients with
LMNA mutations, the diagnosis of muscular dystrophy or a
positive family history of muscular dystrophy was not asso-
ciated with a different incidence of ventricular arrhythmias.
The rate of SVT reported by the Authors was of 17% in
EDMD patients and 19% in non-EDMD patients. More
than 20% of the whole population of this study required
cardiac transplantation during follow-up and this is consist-
ent with previous reports. Hasselberg et al. [11] reported
that 19% of genotyped LMNA patients underwent heart
transplantation during a follow up of 8 years (median age
46 years). The need for heart transplantation in our series
was independent from the involvement of the skeletal
muscle and occurred at a median age of 45 years. Differ-
ently from what observed for other clinical events, neuro-
muscular involvement did not lead to an anticipation in the
timeline and heart transplant was performed at a similar
age in the two groups (median 43 vs 46 years).
In this series, patients with a neuromuscular presenta-
tion had a linear predictable progression over time
(Fig. 7). Specifically, skeletal myopathy developed first,
followed by arrhythmias (A-V block, sick sinus syn-
drome and AF in various combinations) and eventually,
cardiomyopathy. This pattern of progression was not ob-
served in the other patients.
Fig. 7 Timeline of clinical events in the lifetime of patients with LMNA mutations and neuromuscular onset
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The cardiac involvement in X-linked EDMD patients
of our study, compared to patients with LMNA muta-
tions and a neurological onset, was characterized by
higher burden of supraventricular tachyarrhyrhmias and
bradyarrhythmias that occurred at a younger age and a
lower frequency of cardiomyopathy.
Limitations
Referral bias cannot be excluded since this is a study
from a single tertiary centre with a cardiac transplant
program and expertise for management of complex ven-
tricular tachycardias.
Conclusion
In patients with laminopathy, the type of disease onset
was a marker for a different natural history. Specifically,
patients with neuromuscular presentation had an earlier
cardiac involvement, characterized by a linear and
progressive evolution from rhythm disorders (AF and/or
A-V block) to cardiomyopathy. Prevalence of AF and A-
V block was similar, regardless of clinical onset, whereas
sinus node dysfunction was more frequent in EDMD pa-
tients. Patients with neuromuscular onset had a lower
prevalence of cardiomyopathy and ventricular arrhyth-
mias, but a similar prevalence of heart transplantation at
a similar age.
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